Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA5A | P35218 | 2/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL3306696 | 1.00 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL733844 | 1.00 | SLC34A1 (0.58) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL4611532 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL733843 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL166796 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL7871826 | 0.95 | — | — | |
| Phosphoric Acid SCHEMBL7871824 | 0.95 | SLC34A1 (0.54) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL21612686 | 0.95 | SLC34A1 (0.54) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL22116976 | 0.95 | SLC34A1 (0.54) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL5330837 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389933-A1 | Controlled-Release Pregabalin Compositions | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2011-11-30 | — | — | EP | claimed |
| US-8039357-B2 | Integrated circuitry and methods of forming a semiconductor-on-insulator substrate | MICRON TECHNOLOGY, INC. (US) | 2011-10-18 | — | — | US | claimed |
| EP-3190089-B1 | METHOD FOR MANUFACTURING PRODUCT INORGANIC COMPOUND AND PRODUCT INORGANIC COMPOUND | UNIV KYUSHU NAT UNIV CORP (JP) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025229626-A1 | CONTINUOUS SYNTHESIS OF OCTACALCIUM PHOSPHATE | RĪGAS TEHNISKĀ UNIVERSITĀTE (LV) | 2025-11-06 | — | — | WO | disclosed |
| WO-2025229627-A1 | RAPID SYNTHESIS OF OCTACALCIUM PHOSPHATE | RĪGAS TEHNISKĀ UNIVERSITĀTE (LV) | 2025-11-06 | — | — | WO | disclosed |
| WO-2024029412-A1 | SILICA-(CALCIUM PHOSPHATE) COMPOSITE BLOCK BODY, AND METHOD FOR PRODUCING SILICA-(CALCIUM PHOSPHATE) COMPOSITE BLOCK BODY | 国立研究開発法人産業技術総合研究所 | 2024-02-08 | — | — | WO | disclosed |
| US-11730856-B2 | Method of producing product inorganic compound and product inorganic compound | KYUSHU UNIVERSITY NATIONAL UNIVERSITY CORPORATION (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20200147260-A1 | METHOD OF PRODUCING PRODUCT INORGANIC COMPOUND AND PRODUCT INORGANIC COMPOUND | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2020-05-14 | — | — | US | disclosed |
| CN-107242903-A | Multi-fluid cutting tissue method and apparatus | 艾奎比姆有限责任公司 | 2017-10-13 | — | — | CN | disclosed |
| US-20170252480-A1 | METHOD OF PRODUCING PRODUCT INORGANIC COMPOUND AND PRODUCT INORGANIC COMPOUND | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3190089-A1 | METHOD FOR MANUFACTURING PRODUCT INORGANIC COMPOUND AND PRODUCT INORGANIC COMPOUND | Kyushu University, National University Corporation (JP) | 2017-07-12 | — | — | EP | disclosed |
| WO-2007046746-A1 | BIODEGRADABLE OSTEOCHONDRAL IMPLANT | ARTIMPLANT AB (SE) | 2007-04-26 | — | — | WO | disclosed |
| CN-1939298-A | Schuqindin sulfate solid and target preparation and their making method | SHANGHAI DRUG INST CHINESE ACA (CN) | 2007-04-04 | — | — | CN | disclosed |
| WO-2006123213-A1 | MODIFIED RELEASE FORMULATIONS OF GLICLAZIDE | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-23 | — | — | WO | disclosed |
| EP-1285579-B1 | Bactericidal guanidine derivatives, dermally applicable composition, washing composition, and antibacterial fibre aggregate | AJINOMOTO KK (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-20030162838-A1 | Bactericide, antiseptic, dermally applicable composition, washing composition, antibacterial fiber aggregate, method for eradicating a microorganism, and method for inhibiting the proliferation of a microorgamism | AJINOMOTO CO., INC. (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1285579-A1 | Bactericidal guanidine derivatives, dermally applicable composition, washing composition, and antibacterial fibre aggregate | Ajinomoto Co., Inc. (JP) | 2003-02-26 | — | — | EP | disclosed |
| EP-0199912-B1 | PROCESS FOR THE MANUFACTURE OF COARSE-GRAINED DICALCIUM PHOSPHATE DIHYDRATE | Benckiser-Knapsack GmbH (DE) | 1990-01-31 | — | — | EP | disclosed |
| US-4755367-A | Adding aqueous phosphoric acid and suspension of precipitated chalk to dicalcium phosphate dihydrate suspension to form precipitate, removing amount equal to addition, separating | BENCKISER-KNAPSACK GMBH (DE) | 1988-07-05 | — | — | US | disclosed |
| EP-0199912-A2 | Process for the manufacture of coarse-grained dicalcium phosphate dihydrate | Benckiser-Knapsack GmbH (DE) | 1986-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162838-A1 | Bactericide, antiseptic, dermally applicable composition, washing composition, antibacterial fiber aggregate, method for eradicating a microorganism, and method for inhibiting the proliferation of a microorgamism | ARG1, ALKBH1, GANC | SLC34A1 4375/4885LMNA 2863/4885KDM4E 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.